Point72 Europe London LLP Buys Shares of 27,231 BioNTech SE (NASDAQ:BNTX)

Point72 Europe London LLP purchased a new stake in BioNTech SE (NASDAQ:BNTX) during the third quarter, Holdings Channel.com reports. The firm purchased 27,231 shares of the company’s stock, valued at approximately $3,234,000.

A number of other hedge funds have also recently made changes to their positions in BNTX. CANADA LIFE ASSURANCE Co raised its holdings in BioNTech by 79.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,426 shares of the company’s stock worth $316,000 after purchasing an additional 1,518 shares in the last quarter. Tidal Investments LLC purchased a new stake in BioNTech during the first quarter valued at approximately $703,000. EverSource Wealth Advisors LLC boosted its stake in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after acquiring an additional 252 shares in the last quarter. GAMMA Investing LLC grew its holdings in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the last quarter. Finally, Granite Bay Wealth Management LLC acquired a new position in shares of BioNTech during the second quarter worth $1,483,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. TD Cowen lowered their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Canaccord Genuity Group boosted their price target on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday. HSBC increased their price objective on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Berenberg Bank began coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price on the stock. Finally, Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and raised their price target for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Stock Performance

NASDAQ BNTX opened at $118.39 on Friday. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $28.38 billion, a P/E ratio of -56.38 and a beta of 0.26. The stock has a 50-day simple moving average of $113.69 and a two-hundred day simple moving average of $98.50.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period in the previous year, the company posted $0.73 earnings per share. BioNTech’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, equities analysts forecast that BioNTech SE will post -3.68 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.